All Updates

All Updates

icon
Filter
Funding
Neuron23 raises USD 100 million in Series C
AI Drug Discovery
Mar 30, 2022
This week:
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Funding
OceanWell raises USD 11 million in Series A funding to build water farms
Conservation Tech
Yesterday
Product updates
H launches Runner H, an AI agent for business automation
Foundation Models
Yesterday
Partnerships
Capgemini partners with Mistral AI and Microsoft to expand GenAI solutions globally
Foundation Models
Yesterday
Funding
Product updates
Converge Bio launches biotech LLM platform with USD 5.5 million seed funding
Foundation Models
Yesterday
Partnerships
Snowflake partners with Anthropic to integrate Claude AI models into Cortex AI platform
Foundation Models
Yesterday
Product updates
DeepSeek releases AI reasoning model DeepSeek-R1
Foundation Models
Yesterday
Industry news
Partnerships
ICEYE partners with Lockheed Martin and Finnish firms to develop defense space technologies
Next-gen Satellites
Yesterday
Partnerships
Dematic installs AutoStore system at South West Healthcare logistics hub
Logistics Tech
Yesterday
AI Drug Discovery

AI Drug Discovery

Mar 30, 2022

Neuron23 raises USD 100 million in Series C

Funding

  • California-based AI precision biotechnology company Neuron23 has raised USD 100 million in a Series C funding round led by SoftBank Vision Fund 2 with participation from existing investors WestLake Village BioPartners, Kleiner Parkins, and others. This brings the company’s total funds raised to USD 213.5 million.

  • The proceeds will be directed toward advancing the company’s lead programs, bolstering its clinical development team, and developing its precision immunology platform. The funds will also be used to fuel the research on its Parkinson’s drug candidate “NEU-723”—targeting a protein called leucine-rich repeat kinase 2 (LRRK2)—which is expected to enter clinical trials by the end of 2022.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.